Evolution of Phenylketonuria (PKU) Treatment: A Multimodal Approach from Dietary Restriction to Gene Editing
##1. PAH Enzyme Deficiency and the Lifelong Dietary Restriction Dilemma Phenylketonuria (PKU) is an autosomal recessive genetic disorder caused by mutations in the PAH gene, leading to deficiency of the enzyme that converts phenylalanine (Phe) to tyrosine. If left untreated, neurotoxic accumulation in the brain results in severe intellectual disability. The conventional standard of care is a diet that severely restricts phenylalanine intake; however, this approach causes nutritional imbalances and imposes a substantial psychological and social burden—particularly reduced adherence—in growing children and adolescents, representing a critical limitation.
##2. Enzyme Cofactors and Alternative Therapies: From Sapropterin to Pegvaliase The development of pharmacologic therapies has begun to address the limitations of dietary management. Sapropterin, which supplements the PAH cofactor tetrahydrobiopterin (BH4), and its precursor sepiapterin partially restore enzyme activity in mildly affected patients. Moreover, pegvaliase, a plant‑derived enzyme that directly degrades phenylalanine, has dramatically lowered blood Phe concentrations in severely affected adult patients. In addition, a renal phenylalanine reabsorption inhibitor that has entered clinical development offers a completely novel metabolic bypass by promoting urinary excretion of Phe, thereby expanding therapeutic options.
##3. Gene Editing and AAV Therapeutics: A Leap Toward Curative Metabolism Correction The most disruptive innovation is the gene‑level approach. In vivo gene therapy using CRISPR‑Cas systems to directly correct the defective PAH gene in hepatocytes, or delivering a functional PAH gene to the liver via adeno‑associated virus (AAV) vectors, has demonstrated robust efficacy in animal models. This strategy goes beyond symptom management by permanently restoring the liver’s capacity to metabolize phenylalanine, representing an ultimate therapeutic paradigm.
##4. Why it Matters: A Paradigm Shift Toward ‘Metabolic Liberation’ in Disease Management This research trajectory is significant because it elevates the goal of PKU therapy from merely preventing neurotoxicity to achieving complete metabolic freedom for patients. If gene therapy becomes commercially available, patients could be liberated from lifelong restrictive diets and frequent blood monitoring. This represents a flagship example of the clinical value of advanced gene‑editing technologies for rare metabolic disorders and will serve as a leading regulatory and technical milestone for the development of therapies for other inherited metabolic diseases.
Phenylketonuria (PKU) is an autosomal recessive disorder characterised by an inborn error of phenylalanine (Phe) metabolism. Such errors are attributed to pathogenic gene variants causing phenylalanine hydroxylase (PAH) deficiency, impairing the hydroxylation of phenylalanine to tyrosine in the Phe metabolic pathway. This defect leads to plasma Phe concentrations above the normal range. If untreated, hyperphenylalaninemia can adversely affect brain function, leading to severe intellectual disability and seizures. Since 1969, the newborn dried blood spot test has remained the main method of early screening and diagnosis for PKU. The primary therapeutic management is a lifelong phenylalanine-restricted diet with the aim of decreasing plasma Phe levels. The recommended diet consists of avoiding high-protein foods such as meat, fish, eggs and nuts, and can be supplemented with high-protein medical formulas which are low in phenylalanine. Pharmacological interventions such as sapropterin, sepiapterin and pegvaliase can also be used as treatment adjuncts in patients with PKU. Currently, small-molecule inhibitors reducing renal phenylalanine reabsorption are being explored as a potential therapeutic intervention. Furthermore, novel gene-editing techniques are under evaluation as potential curative strategies, with preclinical studies showing promising results in correcting pathogenic phenylalanine hydroxylase variants. This non-systematic review synthesises current literature on the management of PKU, with a focus on dietary interventions and recommendations.
This dataset comprehensively summarizes the technological evolution of metabolic disease therapy by integrating a multi‑target strategy ranging from metabolic bypass (renal reabsorption inhibition) to causal correction (CRISPR/AAV). By systematizing how pharmacologic and genetic approaches complement each other, it provides exceptional scholarly value as a core design guideline for future drug‑development pipelines targeting refractory metabolic disorders.